* Pavmed Inc - co has decided to follow fda s encouragement and pursue a de novo classification for portio under a broader indication, for up to 7 days * Pavmed - ‍ after pursuing de novo ...

NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its ...

NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced that physicians at the Clinica ...

Potential Savings of $95 Million Annually if Only Ten Percent of Central Lines Are Replaced with IO Access Success rate of 96% in establishing vascular access on first attempt; Mean time to vascular ...

March 11, 2008 — The US Food and Drug Administration (FDA) has granted 510(k) clearance for a handheld device for the measurement of airway inflammation, an intraosseous infusion system for use in ...

Pavmed Inc. implanted its Portio system in three patients in a first-in-human (FIH) study of its intraosseous infusion system and successfully infused fluids in all patients without complications. The ...

First three patients underwent successful implantation and clinical utilization of PortIO as part of a first-in-human study in Colombia, South America NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: ...

FDA pre-submission meeting date supporting de novo application secured Broad method and device patents granted by USPTO NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ...

Intraosseous cannulation is an accepted means to achieve vascular access when peripheral venous access is not available. It is common practice to flush the intraosseous cannula with saline prior to ...